BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260909
DTEND;VALUE=DATE:20260911
DTSTAMP:20260515T013451
CREATED:20260512T104607Z
LAST-MODIFIED:20260512T104607Z
UID:43492-1788912000-1789084799@www.pharmajournalist.com
SUMMARY:6th iPSC Drug Development Summit
DESCRIPTION:As iPSC therapies transition from promise to clinical reality\, the 6th iPSC Drug Development Summit arrives at a pivotal moment for biopharma leaders advancing next-generation cell therapies. Bringing together senior scientists\, CMC experts\, and decision-makers\, this industry-focused meeting is dedicated exclusively to accelerating iPSC-based drug development from discovery through clinical translation and commercialization. \nThis year’s agenda is designed to address the most pressing challenges across the iPSC pipeline\, with a sharp focus on scalability\, manufacturability\, and regulatory alignment as therapies move toward late-stage clinical success. Attendees will gain practical insights across two core tracks\, covering preclinical development and process development & CMC\, including genome editing strategies\, donor and cell line selection\, functional quality control\, and GMP-ready manufacturing approaches. \nThe summit features 25+ expert speakers from leading organizations actively advancing iPSC therapies across indications such as Parkinson’s disease\, diabetes\, oncology\, and ocular disorders. \nSpeaker highlights include: \n\nYanzheng Liu\, Senior Director\, Aspen Neuroscience\nRachel Knopp and Yongting Wang\, Astellas Pharma\nWilliam Hendriks\, Director of PSC Biology\, BlueRock Therapeutics\nEric Law\, Head of CMC Regulatory Affairs\, Century Therapeutics\nAlex Ng\, Chief Scientific Officer\, GC Therapeutics\nMarcella Garita-Hernandez\, Head of iPS Core\, Harvard Medical School\n\nWith contributions from organizations including Astellas Pharma\, BlueRock Therapeutics\, Aspen Neuroscience\, Vertex Pharmaceuticals\, and more\, the meeting provides a unique opportunity to learn directly from teams generating clinical data and overcoming real-world development bottlenecks. \nDesigned for professionals actively building iPSC pipelines\, the summit offers an end-to-end view of the field\, alongside collaborative networking with peers across biopharma\, academia\, and investment. From optimizing early discovery decisions to ensuring commercial readiness\, this is the must-attend forum to benchmark strategies and accelerate the path to clinically successful iPSC therapies. \nFind out more here: https://ter.li/japojzin \nThis meeting is free to attend* for biopharma and academics.
URL:https://www.pharmajournalist.com/event/6th-ipsc-drug-development-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR